QR Kod

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

Chemoimmunotherapy followed by consolidative high-dose therapy with autologous stem cell rescue was a standard upfront treatment for fit patients with mantle cell lymphoma (MCL) in first remission; however, treatment paradigms are evolving in the era of novel therapies. Lenalidomide is an immunomod...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Zachary D. Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron, Ahmet Dogan, Pamela Drullinsky, John Gerecitano, Paul A. Hamlin, Caleb Ho, Allison Jacob, Ashlee Joseph, Leana Laraque, Matthew J. Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Chelsea Mullins, Colette Owens, Gilles Salles, Heiko Schöder, David J. Straus, Anas Younes, Andrew D. Zelenetz, Anita Kumar
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2023-08-01
Seri Bilgileri:Haematologica
Online Erişim:https://haematologica.org/article/view/11235
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller